clinical trial · NCT07220915
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Octapharma·phase3·not yet recruiting·n = 360
HypogammaglobulinemiaAutoimmune ConditionsRheumatic ConditionsInfectionsPanzyga, 10% Intravenous SolutionPlacebo
brief summary
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
started
Jun 1, 2026
primary completion
Dec 1, 2029
completion
Dec 1, 2029
last updated
Jun 17, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients With Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment With B-cell Depletion Therapy ("PROTECT")
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol